BRPI0815416A2 - Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos - Google Patents

Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos

Info

Publication number
BRPI0815416A2
BRPI0815416A2 BRPI0815416-3A2A BRPI0815416A BRPI0815416A2 BR PI0815416 A2 BRPI0815416 A2 BR PI0815416A2 BR PI0815416 A BRPI0815416 A BR PI0815416A BR PI0815416 A2 BRPI0815416 A2 BR PI0815416A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
biologically active
active polypeptides
modifying properties
Prior art date
Application number
BRPI0815416-3A2A
Other languages
English (en)
Inventor
Oren Bogin
Willem P Stemmer
Volker Schellenberger
Yong Yin
Chia-Wei Wang
Nathan C Geething
Original Assignee
Amunix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351372&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0815416(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amunix Inc filed Critical Amunix Inc
Publication of BRPI0815416A2 publication Critical patent/BRPI0815416A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
BRPI0815416-3A2A 2007-08-15 2008-08-15 Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos BRPI0815416A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95610907P 2007-08-15 2007-08-15
US98107307P 2007-10-18 2007-10-18
US98656907P 2007-11-08 2007-11-08
PCT/US2008/009787 WO2009023270A2 (en) 2007-08-15 2008-08-15 Compositions and methods for modifying properties of biologically active polypeptides

Publications (1)

Publication Number Publication Date
BRPI0815416A2 true BRPI0815416A2 (pt) 2014-10-21

Family

ID=40351372

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815416-3A2A BRPI0815416A2 (pt) 2007-08-15 2008-08-15 Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos

Country Status (10)

Country Link
US (4) US8933197B2 (pt)
EP (1) EP2185701A4 (pt)
JP (1) JP2010536341A (pt)
KR (1) KR20100058541A (pt)
CN (1) CN103298935A (pt)
AU (1) AU2008287340A1 (pt)
BR (1) BRPI0815416A2 (pt)
CA (1) CA2695374A1 (pt)
MX (1) MX2010001684A (pt)
WO (1) WO2009023270A2 (pt)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
MX2008001054A (es) * 2005-07-28 2008-03-19 Global Res Technologies Llc Eliminacion del dioxido de carbono del aire.
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY
CN116925238A (zh) * 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
LT2440241T (lt) * 2009-06-08 2017-10-10 Amunix Operating Inc. Augimo hormonų polipeptidai ir jų gamybos bei panaudojimo būdai
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
KR101741859B1 (ko) 2009-06-22 2017-06-15 암젠 인크 화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
JP2012531428A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
CA2804755C (en) * 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CA2817671A1 (en) * 2009-11-17 2011-05-26 Universite De Montreal Heteropeptides useful for reducing nonspecific adsorption
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
US20110183891A1 (en) * 2009-12-16 2011-07-28 Jordan Tang Methods and Compositions for Inhibiting Fungal Infection and Disease
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
MX337070B (es) * 2009-12-22 2016-02-11 Celldex Therapeutics Inc Método para preparar un conjugado klh-egfrviii.
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
HUE026229T2 (en) 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2639398T3 (es) 2010-03-04 2017-10-26 Pfenex Inc. Método para producir proteína de interferón recombinante soluble sin desnaturalización
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
EP2552967A4 (en) * 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
US8557961B2 (en) * 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CN102260697A (zh) * 2010-05-26 2011-11-30 重庆富进生物医药有限公司 融合表达重组制备人β干扰素
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
CN103119057B (zh) 2010-06-24 2016-06-15 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2011163650A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a
PE20170938A1 (es) 2010-06-25 2017-07-13 Shire Human Genetic Therapies Suministro al sistema nervioso central de agentes terapeuticos
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
PL3103469T3 (pl) 2010-06-25 2021-09-06 Shire Human Genetic Therapies, Inc. Dostarczanie środków terapeutycznych do OUN
US9670475B2 (en) 2010-07-09 2017-06-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
EP2592997A4 (en) 2010-07-14 2016-09-21 Univ Columbia FORCE-FORCE SPECTROMETER AND METHODS OF USE
WO2012009693A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Ancestral proteins
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
CN103402536A (zh) 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
CA2981662C (en) 2011-01-14 2019-02-05 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
US9394343B2 (en) 2011-07-05 2016-07-19 The Regents Of The University Of California Appetite stimulating protein
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
CN103796670A (zh) 2011-07-08 2014-05-14 比奥根艾迪克依蒙菲利亚公司 因子viii嵌合和杂合多肽及其使用方法
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
BR112014002173A2 (pt) 2011-07-29 2017-03-01 Eleven Biotherapeutics Inc proteínas purificadas
CN103917650B (zh) 2011-08-05 2017-10-24 瑞泽恩制药公司 人源化的通用轻链小鼠
BR112014003268A2 (pt) * 2011-08-11 2017-03-14 Huntsman Petrochemical Llc composição de catalisador amina, formulação de espuma de poliuretano, e, método para a produção de uma de poliuretano
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
WO2013067133A1 (en) * 2011-11-04 2013-05-10 The Texas A & M University System Production of tsg-6 protein
WO2013067652A1 (en) * 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN111499760A (zh) * 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
SI2822577T1 (sl) 2012-02-15 2019-07-31 Bioverativ Therapeutics Inc. Rekombinantni proteini faktorja VIII
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013120553A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
EP3456742A1 (en) 2012-02-15 2019-03-20 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US10421798B2 (en) 2012-02-15 2019-09-24 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
ES2669561T3 (es) 2012-02-17 2018-05-28 University Of Georgia Research Foundation, Inc. Nanopartículas para el transporte mitocondrial de agentes
CN117462693A (zh) * 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
EP2828281B1 (en) * 2012-03-19 2019-09-18 Mileutis Ltd. Peptides for management of lactation
SG10201607369QA (en) 2012-04-20 2016-10-28 Merus Nv Methods and means for the production of ig-like molecules
US20130302366A1 (en) 2012-05-09 2013-11-14 Christopher Marshall Conformationally Specific Viral Immunogens
CN108841802B (zh) 2012-05-11 2023-06-09 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US9907837B2 (en) 2012-05-11 2018-03-06 Gemvax & Kael Co., Ltd. Composition for preventing or treating cachexia
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
LT2859015T (lt) * 2012-06-08 2018-07-10 Alkermes Pharma Ireland Limited Ligandai, modifikuoti cikline permutacija, kaip agonistai ir antagonistai
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
MY185217A (en) 2012-06-21 2021-04-30 Hoffmann La Roche Analogs of glucagon exhibiting gip receptor activity
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
KR101799904B1 (ko) 2012-07-11 2017-11-22 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
KR20150036274A (ko) 2012-07-19 2015-04-07 알레시아 바이오쎄라퓨틱스 인코포레이티드 항-siglec-15 항체
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
EP2892919A1 (en) * 2012-09-07 2015-07-15 Sanofi Fusion proteins for treating a metabolic syndrome
TWI750197B (zh) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
WO2014160371A1 (en) 2013-03-13 2014-10-02 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
CN105263508B (zh) 2013-04-19 2019-10-25 珍白斯凯尔有限公司 治疗和预防缺血性损伤的组合物
EP4063863A1 (en) 2013-06-07 2022-09-28 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
JP2016523978A (ja) * 2013-07-10 2016-08-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸−タンパク質複合体に関する組成物及び方法
WO2015023268A1 (en) * 2013-08-13 2015-02-19 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
US10383921B2 (en) 2013-08-13 2019-08-20 President And Fellows Of Harvard College Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CN110755599A (zh) 2013-10-23 2020-02-07 珍白斯凯尔有限公司 用于治疗和预防良性***增生的组合物
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN104711217B (zh) * 2013-12-13 2018-02-27 天津科技大学 一种新型的促进乳酸菌生长的生物活性肽
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
CN103709253A (zh) * 2013-12-20 2014-04-09 南开大学 一种生物合成制备glp-1及其类似物的方法
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
CN104844711B (zh) * 2014-02-18 2018-07-06 南通表源生物技术有限公司 一种多聚体荧光蛋白复合物及其应用
US9999704B2 (en) * 2014-02-26 2018-06-19 University Of Massachusetts Amphiphilic degradable polymers for immobilization and sustained delivery of biomolecules
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
EP3139955B1 (en) * 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
CA2949535C (en) * 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
HUE047255T2 (hu) * 2014-06-18 2020-04-28 Albert Einstein College Of Medicine Syntac polipeptidek és alkalmazásaik
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
CA2954743C (en) * 2014-07-11 2022-03-15 Metcela Inc. Cardiac cell culture material
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
LT3172232T (lt) 2014-07-17 2024-02-12 Novo Nordisk A/S Į vietą nukreipta trem-1 antikūnų mutagenezė, skirta klampumui sumažinti
CN106999535B (zh) 2014-09-26 2021-12-21 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFκB活性的抑制剂
DK3207130T3 (da) 2014-10-14 2019-11-11 Halozyme Inc Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
WO2016094627A1 (en) 2014-12-10 2016-06-16 S-Aima Holding Company, Llc Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
WO2016149613A2 (en) * 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
MX2017013335A (es) * 2015-07-08 2018-06-06 Research & Business Found Sungkyunkwan Univ Derivados de pirrolidincarboxamido y metodos para prepararlos y usarlos.
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
US10745680B2 (en) 2015-08-03 2020-08-18 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
US11713358B2 (en) 2015-08-28 2023-08-01 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
ES2848478T3 (es) * 2015-09-11 2021-08-09 Biosceptre Uk Ltd Receptores quiméricos para antígenos y usos de estos
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CN108290960B (zh) 2015-10-08 2023-06-09 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017120890A1 (zh) 2016-01-15 2017-07-20 江南大学 一种利用磷脂酶融合表达以提高外源蛋白表达量的方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
MX2019003567A (es) 2016-09-28 2019-12-02 Cohbar Inc Peptidos terapeuticos relacionados con mots-c.
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN108061804B (zh) * 2016-11-09 2020-05-12 北京大学人民医院 用于诊断子宫内膜异位症的生物标志物
IL308851A (en) 2016-12-22 2024-01-01 Cue Biopharma Inc Multimeric polypeptides modulate T cells and methods for their use
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
MX2019009468A (es) 2017-02-08 2020-01-20 Dragonfly Therapeutics Inc Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
WO2018152518A1 (en) 2017-02-20 2018-08-23 Adimab, Llc Proteins binding her2, nkg2d and cd16
WO2018156602A1 (en) * 2017-02-21 2018-08-30 The Regents Of The University Of Michigan Il-22bp compositions and method for the treatment of disease therewith
WO2018156892A1 (en) 2017-02-23 2018-08-30 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
CA3057613A1 (en) * 2017-03-15 2018-09-20 Juneau Biosciences, L.L.C. Methods of using genetic markers associated with endometriosis
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
EA201992226A1 (ru) * 2017-03-22 2020-02-12 Фармейн Корпорейшн Агонисты npra, композиции и их использование
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
CN110505885A (zh) 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
CN107098978A (zh) * 2017-05-05 2017-08-29 中国药科大学 一种抗肿瘤和免疫增强双重功效融合蛋白
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
CN110997711A (zh) * 2017-06-08 2020-04-10 布里格姆妇女医院 用于鉴定表位的方法和组合物
EP3647426A4 (en) * 2017-06-26 2021-04-14 Riken FUSION PROTEIN
WO2019002945A2 (en) * 2017-06-29 2019-01-03 UREKA, Sarl PEPTIDE PRO-MEDICINE HAVING IMPROVED PHARMACEUTICAL PROPERTIES
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. PEPTIDE INHIBITORS OF TAU AGGREGATION
WO2019040411A1 (en) * 2017-08-21 2019-02-28 Indiana University Research And Technology Corporation PROTEIN EXPRESSION SYSTEMS ENHANCING SOLUBILITY
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
KR101930399B1 (ko) * 2017-09-20 2018-12-18 한국과학기술연구원 종양세포 특이적 감응형 자가조립 나노약물복합체
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN111936520A (zh) 2018-04-02 2020-11-13 百时美施贵宝公司 抗trem-1抗体及其用途
EP3553522A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits
KR20210018275A (ko) * 2018-05-07 2021-02-17 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
MX2020012252A (es) * 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
CN108373496A (zh) * 2018-05-17 2018-08-07 安徽工程大学 抗氧化性多肽gtmgavgprg及其制备方法
WO2020033129A1 (en) * 2018-08-07 2020-02-13 Purdue Research Foundation Rejuvenation of car t cell
CN109053862A (zh) * 2018-08-07 2018-12-21 复旦大学附属肿瘤医院 靶向PD-L1的多肽衍生物及其99mTc配合物的制备和应用
EP3852783A1 (en) 2018-09-17 2021-07-28 Massachusetts Institute of Technology Peptides selective for bcl-2 family proteins
KR102201086B1 (ko) * 2018-09-17 2021-01-11 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
CN113195514A (zh) * 2018-10-10 2021-07-30 华盛顿大学 包含混合电荷肽的融合产物和生物缀合物
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
CN109374897B (zh) * 2018-11-22 2021-11-02 大连大学 一种用于肝癌检测的试剂盒
CN109371052B (zh) * 2018-12-04 2022-02-22 安徽农业大学 提高高gc含量噬铜菌属细菌电转化效率的方法
TW202039542A (zh) 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020160003A1 (en) 2019-01-28 2020-08-06 Cohbar, Inc. Therapeutic peptides
CN111499759B (zh) * 2019-01-31 2022-12-20 上海科技大学 一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
CN109627300B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin溶液稳定剂开发及应用
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN110075280A (zh) * 2019-04-30 2019-08-02 王丛飞 一种层粘连蛋白肽复合口服剂及其制备方法
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
US11767524B2 (en) * 2019-09-24 2023-09-26 Abclonal Science, Inc. His-MBP tagged DNA endonuclease for facilitated enzyme removal
CN110658296A (zh) * 2019-10-30 2020-01-07 海南通用三洋药业有限公司 一种醋酸阿托西班注射液中高分子聚合物的检测方法
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US20230043257A1 (en) * 2020-01-21 2023-02-09 Jinyu Zhang Pharmaceutical composition and use thereof
CN111437444B (zh) * 2020-04-12 2021-03-12 南方医科大学 一种抗肠粘连双层生物凝胶制备方法及双层生物凝胶
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN111620942B (zh) * 2020-06-12 2021-10-15 中国科学院昆明动物研究所 布氏鼠耳蝠白三烯A4水解酶抑制剂Motistin的成熟肽及其应用
CN111705032B (zh) * 2020-07-09 2022-04-05 科赫生物科技（北京）有限公司 一种原核表达细胞及其制备方法和应用
CN111870688B (zh) * 2020-07-09 2024-06-11 沣潮医药科技（上海）有限公司 ACE2蛋白与IL-6或TNFα拮抗剂组合及其应用
CN111875711A (zh) * 2020-07-31 2020-11-03 广东昭泰体内生物医药科技有限公司 一种增强型免疫细胞及其应用
JP2023538533A (ja) 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
CN111944021B (zh) * 2020-08-24 2022-03-22 郑州大学 Cd47亲和肽及其应用
WO2022047248A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
WO2022068920A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
CN112375712A (zh) * 2020-11-25 2021-02-19 昆明理工大学 一株乳酸乳球菌及其应用
CN112457399B (zh) * 2020-12-19 2023-09-01 上海佰君生物科技有限公司 一种人免疫球蛋白g的提纯方法
CN113243512A (zh) * 2021-02-10 2021-08-13 渤海大学 一种鲜味肽
CN113024634B (zh) * 2021-03-01 2022-05-10 浙江大学 类肽化合物及其在制备抗生素中的应用
CN113358866B (zh) * 2021-04-22 2023-06-23 四川大学华西医院 基于三重并联杂交链式反应的破伤风抗原的均相超灵敏二维可视化和荧光分析方法及应用
CN117580584A (zh) * 2021-04-29 2024-02-20 禧尔公司 用于富集特定蛋白质子集的肽修饰纳米颗粒
CN113577237B (zh) * 2021-05-25 2023-12-26 浙江大学 类肽化合物在抗多耐药菌、泛耐药菌或全耐药菌中的应用
WO2023008415A1 (ja) * 2021-07-27 2023-02-02 ＳＴＡＮＤ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 ペプチドタグおよび当該ペプチドタグをコードする核酸
CN114133441B (zh) * 2021-11-15 2024-02-06 同济大学 一种促进牙本质矿化的活性短肽及其应用
CN114380902B (zh) * 2021-12-29 2023-06-16 江苏诺泰澳赛诺生物制药股份有限公司 一种hgh(176-191)的制备方法
WO2023212298A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
WO2023212294A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
CN116218711B (zh) * 2022-12-21 2024-02-06 陕西省微生物研究所 一株乳酸乳球菌pz1及其在制备富硒低聚肽中的应用
CN117511889B (zh) * 2023-06-19 2024-04-26 珠海瑞德林生物有限公司 酶及其在非天然氨基酸二肽制备中的应用
CN117603335B (zh) * 2024-01-19 2024-04-30 北京春雷杰创生物科技有限公司 人血清淀粉样蛋白a突变体

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4200984A (en) 1979-03-12 1980-05-06 Fink Ray D Detachable tool combining bracket and method
DE3006377C2 (de) * 1980-02-20 1983-11-24 Franz Josef 6233 Kelkheim Lang Etagenturm
US4398908A (en) 1980-11-28 1983-08-16 Siposs George G Insulin delivery system
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
ATE59302T1 (de) 1984-07-24 1991-01-15 Key Pharma Klebende schicht zur transdermalen freigabe.
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4976696A (en) 1987-08-10 1990-12-11 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5270176A (en) 1987-11-20 1993-12-14 Hoechst Aktiengesellschaft Method for the selective cleavage of fusion proteins with lysostaphin
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
JP2717808B2 (ja) 1988-08-10 1998-02-25 テルモ株式会社 シリンジポンプ
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5017378A (en) 1989-05-01 1991-05-21 The University Of Virginia Alumni Patents Foundation Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5298022A (en) 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
FR2647677B1 (fr) 1989-05-31 1991-09-27 Roussel Uclaf Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5176502A (en) 1990-04-25 1993-01-05 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5089938A (en) * 1991-04-24 1992-02-18 General Motors Corporation Component mounting assembly
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
DK0674506T3 (da) * 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5554730A (en) 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US5578709A (en) 1993-03-09 1996-11-26 Middlesex Sciences, Inc. Macromolecular microparticles and methods of production
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US20020042079A1 (en) 1994-02-01 2002-04-11 Sanford M. Simon Methods and agents for measuring and controlling multidrug resistance
US5739276A (en) 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
PL184531B1 (pl) * 1995-06-07 2002-11-29 Alkermes Inc Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016201A1 (en) 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
IL130822A (en) 1996-10-15 2005-12-18 Elan Pharm Inc N-acyl phosphatidylethanolamine-mediated liposomaldrug delivery
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
ATE314054T1 (de) 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
ES2293473T3 (es) 1998-02-05 2008-03-16 Biosense Webster, Inc. Administracion intracardiaca de farmaco.
US20050260605A1 (en) 1998-02-11 2005-11-24 Maxygen, Inc. Targeting of genetic vaccine vectors
JP2002507393A (ja) 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 抗原ライブラリー免疫
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US6329186B1 (en) 1998-12-07 2001-12-11 Novozymes A/S Glucoamylases with N-terminal extensions
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
IL146798A0 (en) 1999-06-14 2002-07-25 Genentech Inc A structured peptide scaffold for displaying turn libraries on phage
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
KR100902625B1 (ko) 2000-08-15 2009-06-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 마이크로입자
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20030049689A1 (en) 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
IN190699B (pt) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
PE20020908A1 (es) 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
JP2004528345A (ja) 2001-04-30 2004-09-16 シャイア ラボラトリーズ，インコーポレイテッド Ａｃｅ／ｎｅｐインヒビターおよびバイオアベイラビリティーエンハンサーを含む薬学的組成物
US6838093B2 (en) 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
KR100407467B1 (ko) 2001-07-12 2003-11-28 최수봉 리모컨 방식의 인슐린 자동주사기
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
MXPA04003333A (es) 2001-10-10 2006-02-22 Neose Technologies Inc Remodelado y glicoconjugacion de peptidos.
CN100463962C (zh) 2001-12-07 2009-02-25 图尔金株式会社 嵌合蛋白质的表型筛选
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US20070161087A1 (en) 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
SI2932981T1 (sl) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US20080193441A1 (en) 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
WO2005069845A2 (en) 2004-01-14 2005-08-04 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
CN103172747A (zh) 2005-01-25 2013-06-26 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
MX2008012600A (es) 2006-03-31 2008-12-12 Baxter Int Factor viii pegilado.
EP2076604A4 (en) 2006-08-31 2009-09-02 Centocor Ortho Biotech Inc GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
ES2422007T3 (es) 2007-06-21 2013-09-06 Univ Muenchen Tech Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物

Also Published As

Publication number Publication date
EP2185701A4 (en) 2011-03-02
WO2009023270A3 (en) 2009-05-07
US8933197B2 (en) 2015-01-13
US20090092582A1 (en) 2009-04-09
WO2009023270A2 (en) 2009-02-19
EP2185701A2 (en) 2010-05-19
US20100260706A1 (en) 2010-10-14
KR20100058541A (ko) 2010-06-03
CA2695374A1 (en) 2009-02-19
JP2010536341A (ja) 2010-12-02
US20130039884A1 (en) 2013-02-14
MX2010001684A (es) 2010-04-21
AU2008287340A1 (en) 2009-02-19
US20150259431A1 (en) 2015-09-17
CN103298935A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
BRPI0815416A2 (pt) Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
CU23871B1 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0719797A2 (pt) compostos e composições como inibidores de proteína cinase
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BRPI0921320A2 (pt) composições de anticorpo estáveis e métodos para estabilizar os mesmos
BRPI0807918A2 (pt) composições e método para preservação de tecido
BRPI0817200A2 (pt) composições oftálmicas sólida e uso de compostos para fabricação de medicamento
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
BR112012004448A2 (pt) "compostos e composições como inibidores de proteína cinase"
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
EP2152293A4 (en) PROTEIN DELIVERY COMPOSITIONS AND METHODS OF USING THE SAME
BR112012004222A2 (pt) composições pesticidas espumantes e metodos de aplicação
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0810179A2 (pt) Composições de oligo-guluronato e galacturonato
BRPI0911332A2 (pt) composições e uso de inibidores de epas1
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0913441A2 (pt) Composição prebiótica e métodos de produção e uso da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]